BACKGROUND Rotavirus is a leading cause of morbidity and mortality in children younger than 5 years, but there is no effective treatment. We assessed the activity of nitazoxanide, a broad-spectrum anti-infective drug, against rotavirus in cell culture and in a clinical trial in paediatric patients hospitalised with severe rotavirus diarrhoea. METHODS We did a randomised double-blind placebo-c...

Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging. To facilitate the identification of c-Myc inhibitors, we developed a molecular imaging sensor-based high-throughput screening (HTS) system. This system uses a cell-based assay to detect c-Myc activation in a HTS format, which is est...

background: in this study, the efficacy of nitazoxanide in the treatment of helicobacter pylori isolates, which were resistant to metronidazole, was examined.   methods: one hundred twenty two patients who underwent endoscopy examinations at kasra and laleh hospitals in tehran from november 2014 to july 2015 were enrolled. helicobacter pylori strains were isolated from the patients’ endoscopy b...

background: in this study, the efficacy of nitazoxanide in the treatment of helicobacter pylori isolates, which were resistant to metronidazole, was examined.   methods: one hundred twenty two patients who underwent endoscopy examinations at kasra and laleh hospitals in tehran from november 2014 to july 2015 were enrolled. helicobacter pylori strains were isolated from the patients' endoscopy b...

INDIAN PEDIATRICS 1161 VOLUME 42__NOVEMBER 17, 2005 Nitazoxanide (NTZ) is a novel broadspectrum antiparasitic agent originally discovered in 1980s by J.F. Rossignol. Nitazoxanide is effective in broad range of parasitic and protozoal infections including Giardia lamblia, Entamoeba histolytica, Cryptosporidium spp., Ascaris lumbricoides, Hymenolepis nana and Taenia solium/saginata. In combinatio...

Nitazoxanide is a new thiazolide antiparasitic agent that shows excellent in vitro activity against a wide variety of protozoa and helminths. It is given by the oral route with good bioavailability and is well tolerated, with primarily mild gastrointestinal side effects. At present, there are no documented drug-drug interactions. Nitazoxanide has been licensed for the treatment of Giardia intes...

INTRODUCTION Nitazoxanide is a member of a new class of drug, thiazolides, and it was discovered in 1984 with antimicrobial activity effect against anaerobic bacteria, Hepatitis virus, protozoa, and helminths. METHODS A bibliometric study on four databases (1984-2016) - Medline, Scopus, LILACS, and SciELO - characterizing the global scientific production of nitazoxanide. We determined the qua...

Deregulation of c-Myc plays a central role in the tumorigenesis of many human cancers. Yet, the development of drugs regulating c-Myc activity has been challenging. To facilitate the identification of c-Myc inhibitors, we developed a molecular imaging sensor–based high-throughput screening (HTS) system. This systemuses a cell-basedassay todetect c-Myc activation in aHTS format,which is establis...

OBJECTIVE To describe the frequency and antiparasitic in vitro susceptibility of Blastocystis hominis in patients admitted to theHospital Regional Lambayeque, Peru. MATERIAL AND METHODS A cross-sectional study was conducted from January to August 2015 at 313 patients of all ages. B. hominis detection was performed on serial fecal samples by direct microscopic examination and microculture in m...